ExecuPharm selected Delancey as its advisor for our M&A expertise and long-term partnership model. Over several years we partnered with the Company to assess, evaluate and explore strategic alternatives within the context of the rapidly evolving and dynamic pharmaceutical industry. We managed a highly selective and targeted sell-side M&A process and structured and negotiated the terms of the transaction.

Established in 1995, ExecuPharm (www.execupharm.com) provides clients with qualified professionals across functional areas, such as clinical monitoring and study management. The Company also provides core operational activities including onboarding, training, line management, performance management and policy administration. The Company is headquartered in King of Prussia, Pennsylvania, and serves many of the top 20 pharmaceutical corporations, as well as mid-sized and small biopharmaceutical companies.

PAREXEL (www.PAREXEL.com) is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 84 locations in 51 countries around the world, and has approximately 18,600 employees.